Schizophrenia Study In Adults

GlaxoSmithKline (GSK)

Status and phase: Completed; Phase 2

Conditions: Schizophrenia

Treatments: Drug: risperidone; Drug: talnetant

Study type: Interventional

Funder types: Industry

Identifiers

NCT00049946

SB223412/078

Details and patient eligibility

About

A Placebo Controlled Study For Patients With Schizophrenia

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient must meet diagnostic criteria for schizophrenia.

Exclusion criteria

• Patients with other psychotic disorders.
• Patients whose condition is due to the direct physiological effects of a substances (e.g., drug abuse) or a general medical condition.
• Patients with a history of autistic disorder or another pervasive developmental disorder.
• Patients with epilepsy or a history of seizures requiring treatment.
• Patients who are excluded from taking the drug risperidone.
• Patients who pose a current serious suicidal or homicidal risk.
• Patients who are adequately stabilized on their treatment.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind